Reviewer's report

Title: A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

Version: 0 Date: 07 Dec 2019

Reviewer: Vittorio Gebbia

Reviewer's report:

The authors report a phase I-II aimed to evaluate the efficacy and safety of nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced NSCLC without any actionable mutation drivers.

Overall the paper is concise and well written. Methodology is correct but further details should be reported concerning the statistical design of the phase II phase of the study. Moreover authors should comment which is the innovative data of this work since the combination of nab-paclitaxel and platinum salts has been largely reported in medical literature.


Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.

Kenmotsu H1, Yoh K2, Mori K3, Ono A1, Baba T4, Fujiwara Y5, Yamaguchi O6, Ko R7, Okamoto H8, Yamamoto N9, Ninomiya T10, Ogura T4, Kato T11.


Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.

Mazieres J1, Kowalski D2, Luft A3, Vicente D4, Tafreshi A5, Gümüş M6, Laktionov K7, Hermes B8, Cicin I9, Rodríguez-Cid J10, Wilson J11, Kato T12, Ramlau R13, Novello S14, Reddy S15, Kopp HG16, Piperdi B17, Li X17, Burke T17, Paz-Ares L18.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal